Skip to content

Safety and efficacy of remimazolam and alfentanil in the use of self-preserving respiratory anesthesia in elderly men

Safety and efficacy of remimazolam and alfentanil in the use of self-preserving respiratory anesthesia in elderly men

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077044
Enrollment
Unknown
Registered
2023-10-27
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease of prostate

Interventions

Remimazolam+Alfentanil:The anesthesia was induced by remimazolam and alfentanil, and maintained by remimazolam
Remimazolam+Sufentanil:The anesthesia was induced by remimazolam and sufentanil, and maintained by remimazolam
Propofol+Alfentanil:The anesthesia was induced by propofol and alfentanil, and maintained by propofol
Propofol+Sufentanil:The anesthesia was induced by propofol and sufentanil, and maintained by propofol

Sponsors

Changzhou No.2 People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
65 Years to 85 Years

Inclusion criteria

Inclusion criteria: ? Patients undergoing perineal prostate biopsy in Changzhou Second People's Hospital affiliated to Nanjing Medical University; ?ASA grade ?~? ; ?Male patients >65 years of age; ?BMI 18~28kg/?; ?Mallampati grade?~? ;

Exclusion criteria

Exclusion criteria: ? Patients with allergy to sedative and analgesic drugs and contraindications; ? Patients with difficult airway, upper respiratory tract obstruction and disease (tumors, bleeding, patients with peripheral obstructive sleep apnea syndrome (OSAS), nasopharyngeal cavity infection) who were predicted before surgery; ? Patients with recent severe infectious diseases; Patients with bleeding risk (primary thrombocytopenic purpura, hemophilia, long-term use of anticoagulants, etc.); ? Patients with neurological diseases and cognitive behavioral disorders; ? Patients with serious cardiovascular and cerebrovascular diseases;

Design outcomes

Primary

MeasureTime frame
Blood pressure;Heart rate;Oxygen saturation;

Secondary

MeasureTime frame
Nausea and vomiting;Postoperation pain;

Countries

China

Contacts

Public ContactHu Yimin

Changzhou No.2 People's Hospital

guyueym@njmu.cn+86 138 0903 9818

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026